Nuvalent
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 92
- Market Cap
- $5.4B
- Website
- http://www.nuvalent.com
- Introduction
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
NVL-655 for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Conditions
- Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
- Interventions
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06765109
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- Drug: NVL-330
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06521554
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 470
- Registration Number
- NCT05384626
- Locations
- 🇩🇪
Universitatsklinikum Koln - University Hospital Cologne, Cologne, Germany
🇩🇪Universkitatsklinikum Heidelberg - University Hospital Heidelberg, Heidelberg, Germany
🇯🇵Okayama University Hospital, Okayama, Japan
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Conditions
- Metastatic Solid TumorLocally Advanced Solid Tumor
- Interventions
- Drug: NVL-520
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 359
- Registration Number
- NCT05118789
- Locations
- 🇺🇸
UCI Medical Center, Orange, California, United States
🇺🇸Stanford Medicine, Palo Alto, California, United States
🇺🇸Mass General Hospital, Boston, Massachusetts, United States